Who are Kalydeco's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trikafta (Copackaged), Kalydeco, SUZ, Ivacaftor/Ataluren, LUM/IVA, Ivacaftor and Symdeko.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivacaftor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Kalydeco — Competitive Intelligence Brief

Kalydeco (IVACAFTOR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]. Area: Respiratory.

marketed Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] Cystic fibrosis transmembrane conductance regulator Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Kalydeco (IVACAFTOR) — Vertex Pharms Inc. Kalydeco works by helping the defective protein in cystic fibrosis cells function more normally.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kalydeco TARGET	IVACAFTOR	Vertex Pharms Inc	marketed	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	Cystic fibrosis transmembrane conductance regulator	2012-01-01
Trikafta (Copackaged)	ELEXACAFTOR	Vertex Pharms Inc	marketed		Cystic fibrosis transmembrane conductance regulator	2019-01-01
Kalydeco	Kalydeco	Concert Pharmaceuticals	marketed		Cystic fibrosis transmembrane conductance regulator
SUZ	SUZ	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor/Ataluren	Ivacaftor/Ataluren	University of Alabama at Birmingham	marketed	CFTR modulator combination	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)
LUM/IVA	LUM/IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor and Symdeko	Ivacaftor and Symdeko	University of Alabama at Birmingham	marketed	CFTR modulator (potentiator and corrector combination)	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-06 — Trikafta (Copackaged) · 8354427 · US
2026-12-28 — Trikafta (Copackaged) · 8410274 · US
2026-12-28 — Trikafta (Copackaged) · 9931334 · US
2026-12-28 — Trikafta (Copackaged) · 9670163 · US
2026-12-28 — Trikafta (Copackaged) · 8754224 · US
2027-04-09 — Trikafta (Copackaged) · 10239867 · US
2027-04-09 — Trikafta (Copackaged) · 9974781 · US
2027-04-09 — Trikafta (Copackaged) · 11639347 · US
2027-04-09 — Trikafta (Copackaged) · 10022352 · US
2027-05-01 — Trikafta (Copackaged) · 7645789 · US
2027-05-01 — Trikafta (Copackaged) · 8598181 · US
2027-05-01 — Trikafta (Copackaged) · 8623905 · US
2027-05-20 — Trikafta (Copackaged) · 7495103 · US
2027-06-03 — Trikafta (Copackaged) · 7776905 · US
2027-08-05 — Trikafta (Copackaged) · 8324242 · US
2027-11-12 — Trikafta (Copackaged) · 8415387 · US
2029-08-13 — Trikafta (Copackaged) · 10646481 · US
2029-08-13 — Trikafta (Copackaged) · 11564916 · US
2031-03-25 — Trikafta (Copackaged) · 11578062 · US
2031-03-25 — Trikafta (Copackaged) · 10081621 · US
2033-02-27 — Trikafta (Copackaged) · 8883206 · US
2033-02-27 — Trikafta (Copackaged) · 11147770 · US
2033-02-27 — Trikafta (Copackaged) · 10272046 · US
2033-07-15 — Trikafta (Copackaged) · 9012496 · US
2035-10-06 — Trikafta (Copackaged) · 11426407 · US
2035-10-06 — Trikafta (Copackaged) · 10758534 · US
2037-12-08 — Trikafta (Copackaged) · 11517564 · US
2037-12-08 — Trikafta (Copackaged) · 11453655 · US
2037-12-08 — Trikafta (Copackaged) · 10793547 · US
2037-12-08 — Trikafta (Copackaged) · 11179367 · US

Sponsor landscape (Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] class)

Vertex Pharms Inc · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kalydeco — Competitive Intelligence Brief. https://druglandscape.com/ci/ivacaftor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab